In Vitro Replication Inhibitory Activity of Xanthorrhizol against Severe Acute Respiratory Syndrome Coronavirus 2

In spite of the large number of repositioned drugs and direct-acting antivirals in clinical trials for the management of the ongoing COVID-19 pandemic, there are few cost-effective therapeutic options for severe acute respiratory syndrome (SARS) coronavirus 2 (SCoV2) infection. In this paper, we sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Minwoo, Cho, Hee, Ahn, Dae-Gyun, Jung, Hae-Gwang, Seo, Han Young, Kim, Ji-Su, Lee, Youn-Jung, Choi, Jun Yong, Park, In Ho, Shin, Jeon-Soo, Kim, Seong-Jun, Oh, Jong-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615586/
https://www.ncbi.nlm.nih.gov/pubmed/34829954
http://dx.doi.org/10.3390/biomedicines9111725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615586/
https://www.ncbi.nlm.nih.gov/pubmed/34829954
http://dx.doi.org/10.3390/biomedicines9111725

Ejemplares similares